Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: 2020

Transgene and BioInvent present data on next generation oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting

20201109 Transgene BioInvent_SITC BT001_EN

Published 9 November 2020
Categorized as 2020, BT-001, Invir.IO, Press release

Transgene presents e-poster outlining detailed results from the Phase 1b/2 trial of TG4001 in combination with avelumab in advanced HPV-positive cancers at SITC 2020

20201109 – TG4001+avelumab presentation poster SITC – EN

Published 9 November 2020
Categorized as 2020, Press release, TG4001, TG4001

Transgene reports business update and end Q3 2020 financial position

20201105 Transgene Q3 business upradta EN

Published 5 November 2020
Categorized as 2020, Press release

Transgene Presents its Individualized Immunotherapy, TG4050, at the Annual Neoantigen Based Therapies Summit

20201105 TG – Neoantigen summit presentation

Published 5 November 2020
Categorized as 2020, Press release, TG4050

Transgene announces detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers

20201027 – TG4001+avelumab abstract data SITC – EN

Published 27 October 2020
Categorized as 2020, Press release, TG4001, TG4001

Acceptance of Late Breaking Abstract at Upcoming SITC 2020 Conference, on the detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers

20201019 TG4001+avelumab SITC – EN

Published 19 October 2020
Categorized as 2020, Press release, TG4001, TG4001

Transgene and BioInvent to present data on oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting

20201015 – BT-001_SITC poster EN

Published 15 October 2020
Categorized as 2020, BT-001, Press release

Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers

20201006 Transgene_NEC_BostonGene_Press_Release_final

Published 6 October 2020
Categorized as 2020, Myvac, Press release, TG4050

Positive clinical results for TG4001 and TG6002 and financial visibility secured until 2022

20200916 Results H1 2020 EN

Published 16 September 2020
Categorized as 2020, Press release

Transgene Announces Upcoming Investor Meetings

20200909 Next investor events

Published 9 September 2020
Categorized as 2020, Press release

Posts pagination

Newer posts Page 1 Page 2 … Page 5 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu